Total Payments
$11,423
2024 Payments
$1,649
Companies
38
Transactions
562
Medicare Patients
3,061
Medicare Billing
$762,681
Payment Breakdown by Category
Food & Beverage$11,147 (97.6%)
Other$225.00 (2.0%)
Education$50.49 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,147 | 558 | 97.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $225.00 | 1 | 2.0% |
| Education | $50.49 | 3 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,812 | 92 | $0 (2024) |
| QOL Medical, LLC | $1,727 | 67 | $0 (2024) |
| ABBVIE INC. | $1,463 | 74 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,263 | 86 | $0 (2024) |
| NESTLE HEALTHCARE NUTRITION INC. | $463.70 | 21 | $0 (2023) |
| Daiichi Sankyo Inc. | $449.17 | 24 | $0 (2024) |
| Romark Laboratories, LC | $427.03 | 8 | $0 (2019) |
| RedHill Biopharma Inc. | $389.47 | 20 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $322.93 | 18 | $0 (2023) |
| INTERCEPT PHARMACEUTICALS, INC. | $317.16 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,649 | 78 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($420.47) |
| 2023 | $1,924 | 85 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($435.46) |
| 2022 | $1,314 | 65 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($342.28) |
| 2021 | $1,723 | 83 | Nestle HealthCare Nutrition Inc. ($442.38) |
| 2020 | $822.84 | 43 | QOL Medical, LLC ($223.53) |
| 2019 | $1,513 | 71 | Romark Laboratories, LC ($412.56) |
| 2018 | $1,367 | 73 | Shire North American Group Inc ($225.00) |
| 2017 | $1,111 | 64 | Merck Sharp & Dohme Corporation ($299.15) |
All Payment Transactions
562 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $3.37 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: VIROLOGY | ||||||
| 12/13/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $20.44 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Gastroenterology | ||||||
| 12/03/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $29.42 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/02/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/27/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $28.36 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $8.85 | General |
| Category: Gastroenterology | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $8.01 | General |
| Category: Gastroenterology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $34.40 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/07/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: LIVER DISEASE | ||||||
| 11/03/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $4.86 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: Gastroenterology | ||||||
| 10/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 874 | 970 | $692,549 | $207,792 |
| 2022 | 9 | 779 | 805 | $682,159 | $222,791 |
| 2021 | 12 | 661 | 679 | $561,568 | $177,042 |
| 2020 | 9 | 747 | 759 | $536,706 | $155,055 |
Total Patients
3,061
Total Services
3,213
Medicare Billing
$762,681
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Office | 2023 | 106 | 106 | $148,400 | $49,793 | 33.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 135 | 137 | $130,150 | $46,887 | 36.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2023 | 143 | 143 | $157,300 | $42,907 | 27.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2023 | 41 | 41 | $37,968 | $15,810 | 41.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 77 | $23,100 | $8,781 | 38.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 43 | 43 | $47,300 | $7,310 | 15.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 44 | $17,600 | $7,091 | 40.3% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 28 | 28 | $39,200 | $5,553 | 14.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 49 | 50 | $15,000 | $5,077 | 33.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 12 | 12 | $15,000 | $4,503 | 30.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $12,000 | $4,405 | 36.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 49 | 82 | $7,806 | $2,664 | 34.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 31 | 31 | $29,450 | $2,533 | 8.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 27 | $5,400 | $1,979 | 36.6% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 29 | 52 | $4,444 | $1,581 | 35.6% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 26 | 51 | $1,275 | $547.99 | 43.0% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 16 | 16 | $1,155 | $371.52 | 32.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 150 | 151 | $143,450 | $56,363 | 39.3% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Office | 2022 | 112 | 113 | $158,200 | $56,324 | 35.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2022 | 173 | 173 | $190,300 | $55,420 | 29.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2022 | 41 | 41 | $38,459 | $16,895 | 43.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 80 | 80 | $24,000 | $7,139 | 29.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 39 | $15,600 | $6,200 | 39.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 68 | 78 | $15,600 | $6,012 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 46 | $13,800 | $5,150 | 37.3% |
About Dr. Joseph Duva, MD
Dr. Joseph Duva, MD is a Gastroenterology healthcare provider based in Riverhead, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992817977.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Duva, MD has received a total of $11,423 in payments from pharmaceutical and medical device companies, with $1,649 received in 2024. These payments were reported across 562 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($11,147).
As a Medicare-enrolled provider, Duva has provided services to 3,061 Medicare beneficiaries, totaling 3,213 services with total Medicare billing of $762,681. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Riverhead, NY
- Active Since 08/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992817977
Products in Payments
- XIFAXAN (Drug) $1,892
- Sucraid (Drug) $955.28
- SUCRAID (Drug) $771.54
- DIFICID (Drug) $500.55
- INJECTAFER (Drug) $449.17
- ZENPEP (Drug) $442.38
- ZERBAXA (Drug) $412.89
- Alinia (Drug) $412.56
- RINVOQ (Biological) $298.66
- OCALIVA (Drug) $294.72
- MAVYRET (Drug) $258.18
- SKYRIZI (Biological) $252.53
- Linzess (Drug) $245.06
- LINZESS (Drug) $228.05
- VOQUEZNA (Drug) $204.98
- VIBERZI (Drug) $202.80
- Trulance (Drug) $190.24
- Talicia (Drug) $177.09
- Humira (Biological) $164.25
- Movantik (Drug) $161.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.